Studies have shown that mTOR is overexpressed in prostate cancer (Genc et al., 2019; Tan et al., 2017), and mTOR inhibitors have shown positive results in the treatment of prostate cancer in phase I clinical trials (Binal et al., 2020). The gene discussed is MTOR; the disease is prostate carcinoma.